Larimar Therapeutics Stock Plummets Amid Anaphylaxis Concerns Despite Positive Data

Larimar Therapeutics is experiencing a significant decline in stock value due to reports of anaphylaxis cases linked to its Friedreich's Ataxia study, overshadowing positive frataxin data. This situation raises concerns for investors and patients alike, emphasizing the inherent risks in clinical trials and the biotech sector's volatility.